Developer of oral, gut-targeted polymer therapeutics for the treatment of metabolic indications such as type 2 diabetes, and other chronic conditions. The company is developing a lead drug, which is orally administered, non-absorbed, gut-restricted duodenal exclusion therapy designed to replicate the metabolic effects of bariatric surgery with safety-advantages avoiding invasive complications of surgeries and procedures.
Company Details
- Employees
- 9
- Founded
- 2014
- Address
- 600 Suffolk St,
- co****@****end.com
- Industry
- Biotechnology
- Website
- glyscend.com
- HQ
- Lowell, Massachusetts
Glyscend Therapeutics Questions
Glyscend Therapeutics's website is glyscend.com
Glyscend Therapeutics's LinkedIn profile is https://www.linkedin.com/company/glyscend-incorporated
Glyscend Therapeutics has
9 employees.
View email and phone details for 9
employees at Glyscend Therapeutics.
Glyscend Therapeutics's industry is
Biotechnology
Glyscend Therapeutics's top competitors are
Glycologix,
Biomea Fusion,
Cellphire Therapeutics, Inc.,
Regenxbio,
Hememics Biotechnologies, Inc.,
Diogenx,
Cerevance,
Atrogi,
Roosterbio Inc.,
Imcyse Sa.
Glyscend Therapeutics's support email address is contact@glyscend.com
Glyscend Therapeutics's categories are Biotechnology
Glyscend Therapeutics's founding year is 2014
